A randomised Phase III trial testing intravenous administration of Nivolumab (Opdivo®; NCT02017717), an anti-PD-1 antibody, in recurrent GBM patients, alone and in combination with Bevacizumab or the anti-CTLA-4 drug Ipilimumab (Yervoy®), is due for completion in 2018. This evidence concerns the gene CTLA4 and glioblastoma.